Oxford BioMedica signs $100m CAR-T deal with Novartis – pharmaphorum
pharmaphorum |
Oxford BioMedica signs $100m CAR–T deal with Novartis
pharmaphorum The deal represents a major financial boost for the UK biotech firm, which provides bioprocessing services for third parties as well as advancing its own gene and cell therapies. Novartis’ CTL019 could be the first groundbreaking CAR–T to gain approval … Oxford BioMedica and Novartis build on supply deal as CAR–T medication nears finish lineFiercePharma Oxford BioMedica signs major supply deal with NovartisPharmaTimes Oxford BioMedica, Novartis link up on CAR–T drug productionBioPharma Dive |
|
Better than CRISPR? LASSO Cloning ropes in Long-Read DNA
Labiotech.eu (blog) After CRISPR, there’s a new genetic technique with a tongue-in-cheek name in town: LASSO cloning, a method to sequence long DNA fragments. |